The spectrum of HLA-DQ and HLA-DR alleles, 2006: A listing correlating sequence and structure with function

Immunogenetics

Volumn 59, Issue 7, 2007, Pages 539-553

  Bondinas, George P ^a   Moustakas, Antonis K ^b   Papadopoulos, George K ^a  

^a Epirus Institute of Technology Arta   (Greece)

^b IONIAN UNIVERSITY   (Greece)

Author keywords

Antigen presentation; HLA DQ; HLA DR; MHC class II

Indexed keywords

AMINO ACID; CD4 ANTIGEN; HLA DQ ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HOMODIMER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ALLELE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOPLASM; GENE FUNCTION; GENE LOCUS; GENE SEQUENCE; GENE STRUCTURE; GENETIC POLYMORPHISM; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOGENETICS; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPECIES COMPARISON;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; DIMERIZATION; H-2 ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ANALYSIS, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; RATTUS;

EID: 34249810950     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00251-007-0224-8     Document Type: Article

References (119)

1. Andersen LC, Beaty JS, Nettles JW, Seyfried CE, Nepom GT, Nepom BS (1991) Allelic polymorphism in transcriptional regulatory regions of HLA-DQB genes. J Exp Med 215:181-192
2. André P, Cambier JC, Wade TK, Raetz T, Wade WF (1994) Distinct structural compartmentalization of the signal transducing functions of major histocompatibility complex class II (Ia) molecules. J Exp Med 179:763-768
3. Ashman JB, Miller J (1999) A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain. J Immunol 163:2704-2712
4. Beaty JS, Sukkiennicki T, Nepom GT (1999) Allelic variation in transcription modulates MHC class II expression and function. Microbes Infect 1:919-927
5. Benkovic AJ, Garcia KC (2003) Not just any T cell receptor will do. Immunity 18:7-11
6. + T cells: evidence from a lymphopenic T cell model. Immunity 17:425-436
7. Brown JH, Jardetzky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC (1988) A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 332:845-850
8. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC (1993) Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33-39
9. Cammarota G, Scheirle A, Tacaks B et al (1992) Identification of a CD4 binding site on the β2 domain of HLA-DR molecules. Nature 356:799-801
10. Cariolou MA, Manoli P, Christophorou M, Bashiardes E, Karagrigoriou A, Budowle B (1998) Greek Cypriot allele and genotype frequencies for amplitype PM-DQA1 and D1S80 loci. J Forensic Sci 43:661-664
11. Chen F, Xie J, Li N, Zhou Y, Xin L, Chou KY (2005) Novel SLA-DQ alleles and their recombinant molecules in xenogeneic stimulation of human T cells. Transpl Immunol 14:83-89
12. Chia CP, Khrebtukova I, McCluskey J, Wade WF (1994) MHC class II molecules that lack cytoplasmic domains are associated with the cytoskeleton. J Immunol 153:3398-3407
13. Cochran JR, Cameron TO, Stern LJ (2000) The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity 12:241-250
14. g7 and autoimmune diabetes. Science 288:505-511
15. Depoil D et al. (2005) Immunological synapses are versatile structures enabling selective T cell polarization. Immunity 22:185-194
16. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC (1997) X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7:473-481
17. Engering A, Pieters J (2001) Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells. Intl Immunol 13:127-134
18. Ettinger RA, Moustakas AK, Lobaton SD (2004) Open reading frame sequencing and structure-based alignment of polypeptides encoded by RT1-Bb, RT1-Ba, RT1-Db, and RT1-Da alleles. Immunogenetics 56:585-596
19. Fremont DH, Hendrickson WA, Marrack P, Kappler J (1996) Structures of an MHC class II molecule with covalently bound single peptides. Science 272:1001-1004
20. k in complex with a dominant epitope of lysozyme. Immunity 8:305-317
21. Gaur LK, Nepom GT (1996) Ancestral major histocompatibility complex genes beget conserved patterns of localized polymorphisms. Proc Natl Acad Sci USA 93:5380-5383
22. Germain RM (2001) The T-cell receptor for antigen: signaling and ligand discrimination. J Biol Chem 276:35223-35226
23. Ghosh P, Amaya M, Mellins E, Wiley DC (1995) The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378:457-462
24. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML (1999) The immunological synapse: a molecular machine controlling T cell activation. Science 285:221-227
25. Gregers TF, Norden TW, Birkeland HC, Sandlie I, Bakke O (2003) The cytoplasmic tail of invariant chain modulates processing and presentation. Eur J Immunol 33:277-286
26. Hamad AR, O'Herrin SM, Lebowitz MS, Srikrishnan A, Bieler J, Schneck J, Pardoll D (1998) Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 co-receptor. J Exp Med 188:1633-1640
27. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P (1998) The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol 161:3282-3291
28. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW (2005) Unconventional topology of self-peptide-major histocompatibility complex binding of a human autoimmune T cell receptor. Nat Immunol 6:490-496
29. Hayball JD, Lake RA (2005) The immune function of MHC class II molecules mutated in the putative superdimer interface. Mol Cell Biochem 273:1-9
30. u. Immunity 17:83-94
31. Hennecke J, Wiley DC (2002) Structure of a complex of the human α/β T cell receptor (TCR) HA1.7 influenza hemagglutinin peptide and major histocompatibility complex II molecule, HLA-DR4 (DRA1*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J Exp Med 195:571-581
32. Hennecke J, Carfi A, Wiley DC (2000) Structure of a covalently-stabilised complex of a human αβ T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J 19:5611-5624
33. Hirayama K, Matsushita S, Kikuchi I, Iuchi M, Ohta N, Sasazuki T (1987) HLA-DQ is epistatic to HLA-DR in controlling the immune response to schistosomal antigen in humans. Nature 327:426-430
34. Hitbold EM, Roche PA (2002) Trafficking of MHC class II molecules in the late secretory pathway. Curr Opin Immunol 14:30-35
35. Hong SC, Sant'Angelo DB, Dittel BN, Medzhitov R, Yoon ST, Waterbury PG, Janeway CA Jr (1997) The orientation of a T cell receptor to its MHC class II: peptide ligands. J Immunol 159:4395-4402
36. Horton R, Niblett D, Milne S, Palmer S, Tubby B, Trowsdale J, Beck S (1998) Large-scale sequence comparisons reveal unusually high levels of variation in the HLA-DQB1 locus in the class II region of the human MHC. J Mol Biol 282:71-97
37. Hsing LC, Rudensky AY (2005) The lysosomal cysteine proteases in MHC class II antigen processing. Immunol Rev 207:229-241
38. Hynes RO (1992) Integrins: versatility, modulation and signaling in cell adhesion. Cell 69:11-25
39. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ (2005) Immunobiology, 6th edn. Garland Science, London, pp 183-201
40. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC (1996) Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci USA 93:734-738
41. Jasanoff A, Wagner G, Wiley DC (1998) Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. EMBO J 17:6812-6818
42. Jones EY, Fugger L, Strominger JL, Siebold C (2006) MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 6:271-282
43. Kawasaki E, Matsuura N, Eguchi K (2006) Type 1 diabetes in Japan. Diabetologia 49:828-836
44. Khalil I, d'Auriol, L, Gobet M et al (1990) A combination of HLA-DQB Asp57-negative and HLA-DQα Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest 85:1315-1319
45. Kim C-Y, Quarsten H, Bergseng E, Khosla C, Sollid LM (2004) Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 101:4175-4179
46. + T lymphocytes. J Exp Med 173:759-762
47. Krummel MF, Sjaastad MD, Wulfing C, Davis MM (2000) Differential clustering of CD4 and CD3 zeta during T cell recognition. Science 289:1349-1352
48. Kumanovics A, Takada T, Lindahl KF (2003) Genomic organization of the mammalian MHC. Annu Rev Immunol 21:629-657
49. Kupfer A (2006) Signaling in the immunological synpase: defining the optimal size. Immunity 25:11-13
50. Kwok WW, Kovats S, Thurtle P, Nepom GT (1993) HLA-DQ allelic polymorphisms constrain patterns of class II heterodimer formation. J Immunol 150:2263-2272
51. König R (2002) Interactions between MHC molecules and co-receptors of the TCR. Curr Opin Immunol 14:75-83
52. König R, Huang Y-L, Germain RN (1992) MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 356:796-798
53. König R, Shen X, and Germain RN (1995) Involvement of both major histocompatibility complex class II alpha and beta chains indicates a role for ordered oligomerization in T cell activation. J Exp Med 182:779-789
54. Lane PJL, McConnell FM, Schieven GL, Clark EA, Ledbetter JA (1990) The role of class II molecules in human B cell activation: association with phosphatidyl inositol turnover, protein tyrosine phosphorylation and proliferation. J Immunol 144:3684-3692
55. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L (2002) A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3:940-943
56. Latek RR, Suri A, Petzold SJ, Nelson CA, Kanagawa O, Unanue ER, Fremont DH (2000) Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 12:699-710
57. Lee KH, Wucherpfennig KW, Wiley DC (2001) Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2: 501-507
58. Li Y, Li H, Martin R, Mariuzza RA (2000) Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J Mol Biol 304:177-188
59. Li Y, Huang Y, Lue J, Quant JA, Martin R, Mariuzza RA (2005) Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 24:2968-2979
60. Lindstedt R, Monk N, Lombardi G, Lechler R (2001) Amino acid substitutions in the putative MHC class II dimer of dimers' interface inhibit CD4+ T cell activation. J Immunol 166:800-808
61. b. Proc Natl Acad Sci USA 99:8820-8825
62. Marotto R, Shen X, König R (1999) Requirement for efficient interactions between CD4 and MHC class II molecules for survival of resting CD4+ T lymphocytes in vivo and for activation-induced cell death. J Immunol 162:5973-5980
63. Marsh SGE, Parham P, Barber LD (2000) The HLA FactsBook. Academic, London, pp 1-390
64. Matsuoka T, Tabata H, Matsushita S (2001) Monocytes are differentially activated through HLA-DR, -DQ and -DP molecules via mitogen-activated protein kinases. J Immunol 166:2202-2208
65. Maynard J, Peterson K, Wilson DH, Adams EJ, Blondelle SE, Boulanger MJ, Wilson DB, Garcia KC (2005) Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity 22:81-92
66. Metz, DP, Farber DL, König R, Bottomly K (1997) Regulation of memory CD4 T cell adhesion by CD4-MHC class II interaction. J Immunol 159:2567-2573
67. Metzler WJ, Bajorath J, Fenderson W, Shaw SY, Constantine KL, Naemura J, Leytze G, Peach RJ, Lavoie TB, Mueller L, Linsley PS (1997) Solution structure of human CTLA4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Biol 4:527-531
68. MHC-sequencing consortium (1999) Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 401:921-923
69. Mooney N, Grillot-Courvalin C, Hivroz C, Charron D (1989) A role for MHC class II antigens in B-cell activation. J Autoimmun 2(Suppl):215-223
70. Morzycka-Wroblewska E, Harwood JI, Smith JR, Kagnoff MS (1993) Structure and evolution of the promoter regions of the DQA genes. Immunogenetics 37:364-372
71. Mossman KD, Campi G, Groves JT, Dustin ML (2005) Altered TCR signaling from geometrically repatterned immunological synapses. Science 310:1191-1193
72. Mosyak L, Zaller DM, Wiley DC (1998) The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 9:377-383
73. g7 of NOD mouse: pH-dependent changes in specificity at pockets 9 and 6 explain several of the unique properties of this molecule. Diabetologia 43:609-624
74. Moustakas AK, van de Wal Y, Routsias J, Kooy YMC, van Veelen P, Drijfhout JW, Koning F, Papadopoulos GK (2000b) Structure of celiac disease-associated HLA-DQ8 and non-associated HLA-DQ9 alleles in complex with two disease-specific epitopes. Intl Immunol 12:1157-1166
75. Moustakas AK, Papadopoulos GK (2002) Molecular properties of HLA-DQ alleles conferring susceptibility to or protection from IDDM: keys to the fate of beta cells. Am J Medical Genetics 115:37-47
76. Murthy VL, Stern LJ (1997) The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding. Structure 5:1385-1396
77. Nepom GT, Kwok WW (1998) Molecular basis for HLA-DQ associations with IDDM. Diabetes 47:1177-1184
78. Newell MK, Justement LB, Miles CR, Freed JH (1988) Biochemical characterization of proteins that co-purify with class II antigens of the murine MHC. J Immunol 140:1930-1938
79. Ohmura-Oshimo M, Matsuki Y, Aoki M, Goto E, Mito M, Uematsu M, Kakiuchi T, Hotta H, Ishido S (2006) Inhibition of MHC II expression and immune responses by c-MIR. J Immunol 177:341-354
80. Oksenberg JR, Seboun E, Hauser SL (1996) Genetics of demyelinating diseases. Brain Pathol 6:289-302
81. Paliakasis K, Routsias J, Petratos K, Ouzounis C, Kokkinidis M, Papadopoulos GK (1996) Novel structural features of the human histocompatibility molecules HLA-DQ as revealed by modelling based on the published structure of the related molecule HLA-DR1. J Struct Biol 117:145-163
82. Papadopoulos GK, Ouzounis C, Eliopoulos E (1998) RGD sequences in several receptor proteins: novel cell adhesion function for receptors? Int J Biol Macromol 22:51-57
83. Platz P, Jakobsen BK, Morling N, Ryder LP, Svejgaard A, Thomsen M, Christy M, Kromann H, Benn J, Nerup J, Green A, Hauge M (1981) HLA-D and -DR antigens in genetic analysis of insulin dependent diabetes mellitus. Diabetologia 21:108-115
84. Rammensee H-G, Friede T, Stevanoviç S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228 (see also the updated listing on the web: http://www.syfpeithi.de )
85. Reich Z, Boniface JJ, Lyons DS, Borochov N, Wachtel EJ, Davis MM (1997) Ligand-specific oligomerisation of T cell receptor molecules. Nature 387:617-620
86. Reichstetter S, Papadopoulos GK, Moustakas AK, Swanson E, Liu AW, Beheray S, Ettinger RA, Nepom GT, Kwok WW (2002) Mutational analysis of critical residues determining antigen presentation and activation of HLA-DQ0602 restricted T cell clones. Hum Immunol 63:185-193
87. Reinherz EL, Tan K, Tang L, Kern P, Liu J, Xiong Y, Husset RE, Smalyar AS, Hare B, Zhang R, Joachimiak A, Chang HC, Wagner G, Wang J (1999) The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913-1921
88. Riberdy JM, Mostaghel E, Doyle C (1998) Disruption of the CD4-major histocompatibility complex class II interaction blocks the development of CD4+ T cells in vivo. Proc Natl Acad Sci USA 95:4493-4498
89. Rich T, Lawler SE, Lord JM, Blancheteaux VM, Charron DJ, Mooney NA (1997) HLA class II-induced translocation of PKCα and PKCβII isoforms is abrogated following truncation of DRβ cytoplasmic domains. J Immunol 159:3792-3798
90. Robinson J, Marsh SG (2003) HLA informatics. Accessing HLA sequences from sequence data bases. Methods Mol Biol 210:3-21
91. Rosloniec EF, Ivey RA III, Whittington KB, Kang KH, Park H-W (2006) Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol 177:3884-3892
92. Routsias J, Papadopoulos GK (1995) Polymorphic structural features of modelled HLA-DQ molecules segregate according to susceptibility or resistance to IDDM. Diabetologia 38:1251-1261
93. Rubinstein E, Le Naour F, Lagaudrière-Gesbert C, Billard M, Conjeaud H, Boucheid C (1996) CD9, CD63, CD81 and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 26:2657-2665
94. Rudolph MG, Wilson IA (2002) The specificity of TCR/pMHC interaction. Curr Opin Immunol 14:52-65
95. + T cells is receptor dependent and HLA-DQ restricted. Proc Natl Acad Sci USA 88:2598-2602
96. Schick MR, Levy S (1993) The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules. J Immunol 151:4090-4097
97. Scott PC, Gogolin-Ewens KJ, Adams TE, Brandon MR (1991) Nucleotide sequence, polymorphism, and evolution of ovine MHC class II DQA genes. Immunogenetics 34:69-79
98. d-peptide complexes reveal that high affinity can be achieved without large anchor residues. Immunity 8:319-329
99. Siebold C, Hansen BE, Wyer JR, Harlos K, Esnouf RE, Svejgaard A, Bell JI, Strominger JL, Jones EY, Fugger L (2004) Crystal structure of HLA-DQ0602 that protects against Type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci USA 101:1999-2004
100. Shin J-S, Ebersold M, Pyppaert M, Delamarre L, Hartley A, Mellman I (2006) surface expression of MHC class II in dendritic cells is controlled by ubiquination. Nature 444:115-118
101. Smiley ST, Rudensky AY, Glimcher LH, Grusby MJ (1996) Truncation of the class II β-chain cytoplasmic domain influences the level of class II/invariant chain-derived peptide complexes. Proc Natl Acad Sci USA 93:241-244
102. Smith KJ, Pyrdol J, Gauthier L, Wiley DC, Wucherpfennig KW (1998) Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J Exp Med 188:1511-1520
103. Sollid LM, Marcussen G, Ek G et al (1989) Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J Exp Med 169:345-350
104. Sparks AB, Rider JE, Hoffman NG, Fowlkes DM, Quilliam LA, Kay BM (1996) Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCγ, and Grb2. Proc Natl Acad Sci (USA) 93:1540-1544
105. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, Stahl ML, Seehra J, Somers WS, Mosyak L (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune response. Nature 410:608-611
106. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, Wiley DC (1994) Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368:215-221
107. Stratikos E, Mosyak L, Zaller DM, Wiley DC (2002) Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with DR1 by formation of tethered complexes that present enhanced HLA-DM catalysis. J Exp Med 196:173-183
108. Suri A, Lovitch SB, Unanue ER (2005a) The wide diversity and complexity of peptides bound to class II MHC molecules. Curr Opin Immunol 17:1-8
109. g7 molecules show common sequence specificity. J Clin Invest 115:2268-2276
110. Szewczuk Z, Siemion IZ, Wieczorek Z (1996) Immunological properties of the thymopentin-like fragments of HLA-DQ. Mol Immunol 33:903-908
111. Szewczuk Z, Wilczynski A, Stefanovwicz P, Fedorowicz W, Siemion IZ, Wieczorek Z (1999) Immunosuppressory mini-regions of HLA-DP and HLA-DR. Mol Immunol 36:525-533
112. Thorsby E, Rønningen KS (1993) Particular HLA-DQ molecules play a dominant role in determining susceptibility or resistance to type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:371-377
113. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L, et al (1988) A molecular basis for MHC Class II-associated autoimmunity. Science 240:1003-1009
114. van de Wal Y, Kooy YM, Drijfhout JW, Amons R, Papadopoulos GK, Koning F (1997) Unique peptide binding characteristics of the disease-associated DQ(alpha 1*0501, beta 1*0201) vs the non-disease-associated DQ(alpha 1*0201, beta 1*0202) molecule. Immunogenetics 46:484-492
115. Vartdal F, Johansen BH, Friede T, Thorpe CJ, Stevanovic S, Eriksen JE, Sletten K, Thorsby E, Rammensee HG, Sollid LM (1996) The peptide binding motif of the disease associated HLA-DQ (alpha 1*0501, beta 1*0201) molecule. Eur J Immunol 26:2764-2772
116. Vogt A, Spindeldrecher S, Kropshofer H (2002) Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains. Immunol Rev 189:136-151
117. Wang J-h, Meijers R, Xiong Y, Liu J-h, Sakihama T, Zhang R, Joachimiak A, Reinherz EL (2001) Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc Natl Acad Sci USA 98:10799-10804
118. Xiong Y, Kem P, Chiang HC, Reinherz EL (2001) T cell receptor binding to a pMHCII ligand is kinetically distinct from and independent of CD4. J Biol Chem 276:5659-5667
119. b peptide-binding motif. J Mol Biol 326:1157-1174